Skip to main content
padlock icon - secure page this page is secure

Management of patients with previously untreated chronic lymphocytic leukaemia with obinutuzumab and chlorambucil

Buy Article:

$52.00 + tax (Refund Policy)

Patients with chronic lymphocytic leukaemia (CLL) are generally older, with many considered ‘unfit’ for fludarabine–cyclophosphamide–rituximab therapy. In these patients, the combination of obinutuzumab–chlorambucil may be an appropriate therapeutic choice. Obinutuzumab–chlorambucil has been demonstrated to improve overall survival rates compared to chlorambucil alone and to improve progression‐free survival and overall response rates compared to rituximab–chlorambucil. This combination can lead to certain toxicities that need to be addressed through appropriate patient selection, pre‐medication and management. In this paper, we discuss evidence‐based and author‐recommended practical management of first‐line CLL patients receiving obinutuzumab–chlorambucil.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: CLL; anti‐CD20; monoclonal antibody; obinutuzumab; rituximab

Document Type: Research Article

Publication date: July 1, 2017

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more